Aerodynamically light particles for pulmonary drug delivery
    1.
    发明申请
    Aerodynamically light particles for pulmonary drug delivery 审中-公开
    用于肺部药物递送的空气动力学轻微颗粒

    公开(公告)号:US20050244341A1

    公开(公告)日:2005-11-03

    申请号:US11177719

    申请日:2005-07-08

    摘要: Improved aerodynamically light particles for delivery to the pulmonary system, and methods for their preparation and administration are provided. In a preferred embodiment, the aerodynamically light particles are made of a biodegradable material and have a tap density less than 0.4 g/cm3 and a mass mean diameter between 5 μm and 30 μm. The particles may be formed of biodegradable materials such as biodegradable polymers. For example, the particles may be formed of a functionalized polyester graft copolymer consisting of a linear a-hydroxy-acid polyester backbone having at least one amino acid group incorporated herein and at least on poly(amino acid) side chain extending from an amino acid group in the polyester backbone. In one embodiment, aerodynamically light particles having a large mean diameter, for example greater than 5 μm, can be used for enhanced delivery of a therapeutic or diagnostic agent to the alveolar region of the lung. The aerodynamically light particles optionally can incorporate a therapeutic or diagnostic agent, and may be effectively aerosolized for administration to the respiratory tract to permit systemic or local delivery of a wide variety of incorporated agents.

    摘要翻译: 提供用于递送至肺系统的改善的空气动力学轻微颗粒,以及其制备和给药方法。 在优选的实施方案中,空气动力学轻微颗粒由可生物降解的材料制成,并且振实密度小于0.4g / cm 3,质量平均直径在5μm和30μm之间。 颗粒可以由可生物降解的材料如可生物降解的聚合物形成。 例如,颗粒可以由官能化的聚酯接枝共聚物形成,所述官能化聚酯接枝共聚物由具有至少一个引入本文的氨基酸基团和至少在从氨基酸延伸的聚(氨基酸)侧链上的直链α-羟基酸聚酯主链组成 集团在聚酯骨干。 在一个实施方案中,具有大平均直径(例如大于5μm)的空气动力学轻的颗粒可用于增强治疗或诊断剂递送至肺的肺泡区域。 空气动力学轻微颗粒任选地可以掺入治疗剂或诊断剂,并且可以有效地雾化用于给予呼吸道以允许各种并入药剂的全身或局部递送。

    Stable spray-dried protein formulations
    2.
    发明申请
    Stable spray-dried protein formulations 审中-公开
    稳定的喷雾干燥蛋白制剂

    公开(公告)号:US20060002996A1

    公开(公告)日:2006-01-05

    申请号:US11176841

    申请日:2005-07-07

    IPC分类号: A61K38/28 A61K9/127

    摘要: Spray-dried particles having improved protein stability are produced by spray-drying a mixture including a protein, a phospholipid and an organic-aqueous co-solvent. Spray-dried particles which include at least 1 weight % phospholipid, having a tap density of less than 0.4 g/cm3 can be prepared. The particles can be delivered to the pulmonary system of a patient.

    摘要翻译: 具有改善的蛋白质稳定性的喷雾干燥颗粒通过喷雾干燥包括蛋白质,磷脂和有机 - 水性共溶剂的混合物而产生。 包含至少1重量%磷脂的喷雾干燥颗粒,其振实密度小于0.4g / cm 3,可以制备。 颗粒可以输送到患者的肺部系统。

    Vehicle floor assembly with insert
    4.
    发明授权
    Vehicle floor assembly with insert 失效
    车载地板总成与插入

    公开(公告)号:US08641128B2

    公开(公告)日:2014-02-04

    申请号:US12537294

    申请日:2009-08-07

    申请人: David Edwards

    发明人: David Edwards

    IPC分类号: B62D27/02 E04C5/16

    CPC分类号: B62D25/2054

    摘要: An insert that can be used support a vehicle floor if a cross member fails either mechanically or through corrosion. The insert may also be used to protect a fastener used in a vehicle floor assembly.

    摘要翻译: 如果交叉构件机械地或通过腐蚀失效,则可以使用的插入件支撑车辆底板。 插入件也可用于保护用于车辆地板组件中的紧固件。

    Method and device for decreasing contamination

    公开(公告)号:US20080038207A1

    公开(公告)日:2008-02-14

    申请号:US11827031

    申请日:2007-07-10

    IPC分类号: A61K31/70 A01N37/18

    CPC分类号: A61B5/097 G01N33/497

    摘要: Methods and devices to determine rate of particle production and the size range for the particles produced for an individual are described herein. The device (10) contains a mouthpiece (12), a filter (14), a low resistance one-way valve (16), a particle counter (20) and a computer (30). Optionally, the device also contains a gas flow meter (22). The data obtained using the device can be used to determine if a formulation for reducing particle exhalation should be administered to an individual. This device is particularly useful prior to and/or following entry in a cleanroom to ensure that the cleanroom standards are maintained. The device can also be used to identify animals and humans who have an enhanced propensity to exhale aerosols (referred to herein as “over producers”, “super-producers”, or “superspreaders”). Formulations to reduce particle production are also described herein. The formulation is administered in an amount sufficient to alter biophysical properties in the mucosal linings of the body. When applied to mucosal lining fluids, the formulation alters the physical properties such as the gel characteristics at the air/liquid interface, surface elasticity, surface viscosity, surface tension and bulk viscoelasticity of the mucosal lining. The formulation is administered in an effective amount to minimize ambient contamination due to particle formation during breathing, coughing, sneezing, or talking, which is particularly important in cleanroom applications. In one embodiment, the formulation for administration is a non-surfactant solution. In one embodiment, the formulations are conductive formulations containing conductive agents, such as salts, ionic surfactants, or other substances that are in an ionized state or easily ionized in an aqueous or organic solvent environment. Preferably the formulation is administered in the form of an aerosol.